ATE548383T1 - Diagnose und behandlung von karzinomen und anderen leiden - Google Patents

Diagnose und behandlung von karzinomen und anderen leiden

Info

Publication number
ATE548383T1
ATE548383T1 AT08156593T AT08156593T ATE548383T1 AT E548383 T1 ATE548383 T1 AT E548383T1 AT 08156593 T AT08156593 T AT 08156593T AT 08156593 T AT08156593 T AT 08156593T AT E548383 T1 ATE548383 T1 AT E548383T1
Authority
AT
Austria
Prior art keywords
carcinoma
diagnosis
treatment
conditions
proline
Prior art date
Application number
AT08156593T
Other languages
English (en)
Inventor
Angus Gidley-Baird
Julian Alexander Barden
Original Assignee
Biosceptre Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPR2579A external-priority patent/AUPR257901A0/en
Priority claimed from AUPR5890A external-priority patent/AUPR589001A0/en
Priority claimed from AUPR5891A external-priority patent/AUPR589101A0/en
Priority claimed from AUPR7430A external-priority patent/AUPR743001A0/en
Priority claimed from AUPR7431A external-priority patent/AUPR743101A0/en
Application filed by Biosceptre Int Ltd filed Critical Biosceptre Int Ltd
Application granted granted Critical
Publication of ATE548383T1 publication Critical patent/ATE548383T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
AT08156593T 2001-01-17 2002-01-17 Diagnose und behandlung von karzinomen und anderen leiden ATE548383T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AUPR2579A AUPR257901A0 (en) 2001-01-17 2001-01-17 Diagnosis and treatment of malignant lymphoma
AUPR5890A AUPR589001A0 (en) 2001-06-22 2001-06-22 An antibody cancer therapeutic
AUPR5891A AUPR589101A0 (en) 2001-06-22 2001-06-22 Diagnosis of cell cancers using an antibody to non-functionalP2X, receptors
AUPR7430A AUPR743001A0 (en) 2001-09-03 2001-09-03 Diagnosis and treatment of irritable bowel syndrome
AUPR7431A AUPR743101A0 (en) 2001-09-03 2001-09-03 A cancer therapeutic

Publications (1)

Publication Number Publication Date
ATE548383T1 true ATE548383T1 (de) 2012-03-15

Family

ID=27507500

Family Applications (2)

Application Number Title Priority Date Filing Date
AT08156593T ATE548383T1 (de) 2001-01-17 2002-01-17 Diagnose und behandlung von karzinomen und anderen leiden
AT02715313T ATE418565T1 (de) 2001-01-17 2002-01-17 Antikörper gegen nichtfunktionelle p 2 x 7 rezeptoren, diagnose und behandlung von krebs und anderen leiden

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT02715313T ATE418565T1 (de) 2001-01-17 2002-01-17 Antikörper gegen nichtfunktionelle p 2 x 7 rezeptoren, diagnose und behandlung von krebs und anderen leiden

Country Status (14)

Country Link
US (10) US7326415B2 (de)
EP (2) EP1961767B1 (de)
JP (2) JP4384852B2 (de)
CN (2) CN101555283B (de)
AT (2) ATE548383T1 (de)
AU (1) AU2003235005B2 (de)
CA (1) CA2434490C (de)
DE (1) DE60230482D1 (de)
DK (2) DK1360203T3 (de)
ES (2) ES2320421T3 (de)
MY (1) MY158262A (de)
PT (1) PT1360203E (de)
TW (1) TWI319011B (de)
WO (1) WO2002057306A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP991199A0 (en) * 1999-04-21 1999-05-13 University Of Sydney, The Methods for diagnosing pre-cancerous and cancerous conditions
AUPR201500A0 (en) * 2000-12-11 2001-01-11 Biosceptre Pty Ltd Methods for identifying pre-neoplastic and neoplastic states in mammals
WO2003020762A1 (en) * 2001-09-03 2003-03-13 Intreat Pty Limited Antibodies to non-functional p2x7receptor, diagnosis and treatment of cancers and other conditions
CN101555283B (zh) 2001-01-17 2012-03-21 生物权威国际有限公司 针对非功能性p2x7受体的抗体及其在癌症和其它病情的诊断和治疗中的用途
ES2386386T3 (es) * 2001-12-12 2012-08-20 Novartis Vaccines And Diagnostics S.R.L. Inmunización contra Chlamydia trachomatis
GB0229139D0 (en) * 2002-12-13 2003-01-15 Glaxo Group Ltd Gene polymorphisms
WO2007146061A2 (en) * 2006-06-09 2007-12-21 University Hospitals Of Cleveland Cell collection and disease screening
WO2008043145A1 (en) * 2006-10-10 2008-04-17 Biosceptre International Limited Hybridomas producing antibodies against non functional p2x7 receptor
US20100036101A1 (en) * 2006-10-10 2010-02-11 Angus Gidley-Baird Antibodies against non functional p2x7 receptor
AU2013238152B2 (en) * 2007-09-14 2015-09-24 Biosceptre International Limited Purinergic (P2X) receptors in extra-cellular body fluid
WO2009033234A1 (en) * 2007-09-14 2009-03-19 Biosceptre International Limited Purinergic (p2x) receptors in extra-cellular body fluid
JP5670192B2 (ja) * 2007-09-14 2015-02-18 バイオセプター・インターナショナル・リミテッド 新規p2x7エピトープ
AU2009266430B2 (en) * 2008-07-04 2014-08-14 Biosceptre International Limited Anti- P2X7 peptides and epitopes
CA2747644C (en) * 2008-12-19 2023-01-24 Ablynx N.V. Method for generation of immunoglobulin sequences
EP3395832B1 (de) 2009-08-20 2021-11-24 Biosceptre (Aust) Pty Ltd Anti-p2x7-rezeptor-antikörper und fragmente davon
WO2011056561A1 (en) 2009-10-27 2011-05-12 Beth Israel Deaconess Medical Center Methods and compositions for the generation and use of conformation-specific antibodies
EP2516470B1 (de) 2009-12-24 2018-02-07 Biosceptre (Aust) Pty Ltd Antikörper gegen nichtfunktionelle oligomere p2x7-rezeptoren
WO2012031333A1 (en) 2010-09-10 2012-03-15 Biosceptre International Limited Companion animal treatments
US10487114B2 (en) 2011-04-27 2019-11-26 Beth Israel Deaconess Medical Center, Inc. Methods for administering peptides for the generation of effective c/s conformation-specific antibodies to a human subject in need thereof
WO2013003895A1 (en) * 2011-07-01 2013-01-10 Biosceptre International Limited Combination therapy
US12121539B2 (en) 2015-09-11 2024-10-22 Biosceptre (Aust) Pty Ltd Chimeric antigen receptors and uses thereof
CN109862883A (zh) 2016-10-21 2019-06-07 生物权威(英国)有限公司 细胞毒性颗粒
AU2019227607C1 (en) 2018-02-27 2023-07-20 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
EP3810610A1 (de) 2018-05-18 2021-04-28 Incyte Corporation Kondensierte pyrimidinderivate als a2a/a2b-inhibitoren
CN117304191A (zh) 2018-07-05 2023-12-29 因赛特公司 作为a2a/a2b抑制剂的稠合吡嗪衍生物
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
CN110054691B (zh) * 2019-05-09 2021-09-07 潍坊医学院 一种抗人p2rx7单克隆抗体的杂交瘤细胞系
JP7853205B2 (ja) * 2019-07-26 2026-04-28 バイオセプター (オースト) プロプライエタリー・リミテッド P2x7受容体の標的療法
CR20220317A (es) 2020-01-03 2022-09-02 Incyte Corp Anticuerpos anti-cd73 y usos de estos
EP4084870A1 (de) 2020-01-03 2022-11-09 Incyte Corporation Cd73-inhibitor und a2a/a2b-adenosinrezeptor-inhibitorkombinationstherapie
JP2024502005A (ja) 2020-12-29 2024-01-17 インサイト・コーポレイション A2a/a2b阻害剤、pd-1/pd-l1阻害剤、及び抗cd73抗体を含む併用療法
BR112023020659A2 (pt) * 2021-04-08 2023-12-05 Biosceptre Aust Pty Ltd Métodos para controlar a atividade de célula imune
US20260085104A1 (en) * 2022-09-14 2026-03-26 Biosceptre (Aust) Pty Ltd Methods of detecting immune cells
CN120187461A (zh) * 2022-09-14 2025-06-20 生物权威(澳大利亚)有限责任公司 免疫细胞的体内检测
JP2025531675A (ja) * 2022-09-14 2025-09-25 バイオセプター (オースト) プロプライエタリー・リミテッド 操作された免疫細胞の富化

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1141314A (en) * 1914-12-19 1915-06-01 Eugene W Caldwell Photographic developing apparatus.
US2191508A (en) * 1939-02-06 1940-02-27 Stuart Robert Photographic film carrier and development receptacle
US3010460A (en) * 1958-07-03 1961-11-28 Geo B Hart Inc Apparatus for wetting absorbent bodies for moistening and supporting plant parts
US3077155A (en) * 1960-08-08 1963-02-12 Pako Corp Device for treating photographic sheet material
US3121438A (en) * 1961-01-16 1964-02-18 Union Carbide Corp Open head container and cover therefor
US3952756A (en) * 1974-06-14 1976-04-27 Purex Corporation Semi automatic parts cleaning machine
US4302273A (en) * 1980-06-04 1981-11-24 Rca Corporation Etching tank in which the solution circulates by convection
US4305413A (en) * 1980-07-25 1981-12-15 Ecology, Inc. Cleaning apparatus
US4550579A (en) * 1984-04-13 1985-11-05 Frank Clifford G Apparatus for the dyeing of shaped articles
US5104727A (en) * 1989-06-16 1992-04-14 W. L. Gore & Associates, Inc. Air bag laminates
IE920765A1 (en) 1991-03-12 1992-09-23 Scripps Research Inst Cell surface receptors homologous to coagulation factors v¹and viii
JPH0756015A (ja) * 1993-08-18 1995-03-03 Sony Corp カラーフィルタの製造方法
EP0760850A1 (de) 1994-05-27 1997-03-12 Glaxo Group Limited P2x REZEPTOREN (PURINOCEPTORENFAMILIE)
US5660640A (en) * 1995-06-16 1997-08-26 Joray Corporation Method of removing sputter deposition from components of vacuum deposition equipment
US5981218A (en) 1995-08-09 1999-11-09 Bristol-Myers Squibb Company Isolated nucleic acid molecules useful as leukemia markers and in breast cancer prognosis and encoded polypeptides
JP2001521372A (ja) 1996-04-30 2001-11-06 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ヒトP2x4レセプタースプライス−変異体
US6303338B1 (en) 1996-08-16 2001-10-16 Human Genome Sciences, Inc. Pancreas-derived plasminogen activator inhibitor
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
JP3885177B2 (ja) 1997-03-26 2007-02-21 大塚製薬株式会社 ヒト遺伝子
US5851307A (en) * 1997-04-28 1998-12-22 Advanced Micro Devices, Inc. Method for in-situ cleaning of polysilicon-coated quartz furnaces
US6133434A (en) * 1997-04-28 2000-10-17 Glaxo Group Limited Purinergic receptor
US5849091A (en) * 1997-06-02 1998-12-15 Micron Technology, Inc. Megasonic cleaning methods and apparatus
US5906216A (en) * 1997-10-10 1999-05-25 Barlet; Bruce N. Denture cleaning device
DE69941187D1 (de) * 1998-06-01 2009-09-10 Agensys Inc Serpentintransmembranantigene exprimiert in menschlichem krebs und deren verwendungen
DE19829473C2 (de) 1998-07-01 2000-08-10 Magnus Von Knebel Doeberitz Ch Verfahren zur frühen Diagnose von Carcinomen
US6055694A (en) * 1998-11-30 2000-05-02 Tsk America, Inc. Wafer scrubbing machine
EP1157038A4 (de) 1999-02-26 2005-01-19 Smithkline Beecham Corp KLONIERUNG EINES P2Y-äHNLICHEN 7TM-REZEPTORS (AXOR17)
AUPP991199A0 (en) 1999-04-21 1999-05-13 University Of Sydney, The Methods for diagnosing pre-cancerous and cancerous conditions
NL1012452C2 (nl) 1999-06-28 2001-01-02 Univ Delft Tech Werkwijze voor de bereiding van eiwit-agglomeraten, eiwit-agglomeraten, een levensmiddel en een farmaceutisch preparaat die deze bevatten alsmede een inrichting voor het bereiden van eiwit-agglomeraten.
WO2001030964A2 (en) 1999-10-22 2001-05-03 Lifespan Biosciences, Inc. Anti-cancer nucleic acid and protein targets
AUPR201500A0 (en) 2000-12-11 2001-01-11 Biosceptre Pty Ltd Methods for identifying pre-neoplastic and neoplastic states in mammals
CN101555283B (zh) 2001-01-17 2012-03-21 生物权威国际有限公司 针对非功能性p2x7受体的抗体及其在癌症和其它病情的诊断和治疗中的用途
WO2003020762A1 (en) 2001-09-03 2003-03-13 Intreat Pty Limited Antibodies to non-functional p2x7receptor, diagnosis and treatment of cancers and other conditions
PL1469072T3 (pl) 2003-04-17 2008-03-31 Affectis Pharmaceuticals Ag Środki i sposoby diagnozowania i leczenia chorób afektywnych
US20090215727A1 (en) 2005-05-05 2009-08-27 Medicure International Inc. Inhibition of atp-mediated, p2x7 dependent pathways by pyridoxal-5-phosphate and vitamin b6 related compounds
US7767789B2 (en) * 2005-06-02 2010-08-03 University Hopitals of Cleveland Truncated proteins as cancer markers
WO2007027957A2 (en) 2005-08-31 2007-03-08 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
WO2008043145A1 (en) 2006-10-10 2008-04-17 Biosceptre International Limited Hybridomas producing antibodies against non functional p2x7 receptor
US20100036101A1 (en) 2006-10-10 2010-02-11 Angus Gidley-Baird Antibodies against non functional p2x7 receptor
WO2009033234A1 (en) 2007-09-14 2009-03-19 Biosceptre International Limited Purinergic (p2x) receptors in extra-cellular body fluid
JP5670192B2 (ja) 2007-09-14 2015-02-18 バイオセプター・インターナショナル・リミテッド 新規p2x7エピトープ
AU2009266430B2 (en) 2008-07-04 2014-08-14 Biosceptre International Limited Anti- P2X7 peptides and epitopes
EP3395832B1 (de) 2009-08-20 2021-11-24 Biosceptre (Aust) Pty Ltd Anti-p2x7-rezeptor-antikörper und fragmente davon
EP2516470B1 (de) 2009-12-24 2018-02-07 Biosceptre (Aust) Pty Ltd Antikörper gegen nichtfunktionelle oligomere p2x7-rezeptoren
WO2011131472A1 (en) 2010-04-22 2011-10-27 Institut Gustave Roussy Compounds and uses thereof to induce an immunogenic cancer cell death in a subject
WO2012031333A1 (en) 2010-09-10 2012-03-15 Biosceptre International Limited Companion animal treatments
WO2013003895A1 (en) 2011-07-01 2013-01-10 Biosceptre International Limited Combination therapy

Also Published As

Publication number Publication date
CN100497385C (zh) 2009-06-10
CN1541222A (zh) 2004-10-27
JP4457169B2 (ja) 2010-04-28
ES2320421T3 (es) 2009-05-22
HK1138013A1 (en) 2010-08-13
EP1961767A2 (de) 2008-08-27
US20170327592A1 (en) 2017-11-16
US20200071419A1 (en) 2020-03-05
US7531171B2 (en) 2009-05-12
US20150274839A1 (en) 2015-10-01
CN101555283B (zh) 2012-03-21
US20080131438A1 (en) 2008-06-05
WO2002057306A1 (en) 2002-07-25
US8080635B2 (en) 2011-12-20
EP1360203A1 (de) 2003-11-12
US20110092674A1 (en) 2011-04-21
EP1360203B1 (de) 2008-12-24
JP2004528286A (ja) 2004-09-16
MY158262A (en) 2016-09-30
US10450380B2 (en) 2019-10-22
TWI319011B (en) 2010-01-01
ATE418565T1 (de) 2009-01-15
HK1123311A1 (en) 2009-06-12
US20130245226A1 (en) 2013-09-19
US8709425B2 (en) 2014-04-29
US8399617B2 (en) 2013-03-19
US9663584B2 (en) 2017-05-30
US20040142342A1 (en) 2004-07-22
DK1961767T3 (da) 2012-05-29
PT1360203E (pt) 2009-04-03
US7888473B2 (en) 2011-02-15
EP1360203A4 (de) 2005-06-22
US20140323693A1 (en) 2014-10-30
US20120059151A1 (en) 2012-03-08
US20090192293A1 (en) 2009-07-30
JP2009235074A (ja) 2009-10-15
AU2003235005A1 (en) 2003-09-11
CA2434490C (en) 2014-06-03
DK1360203T3 (da) 2009-04-20
AU2003235005B2 (en) 2007-09-20
ES2383712T3 (es) 2012-06-25
AU2003235005A8 (en) 2003-09-11
EP1961767B1 (de) 2012-03-07
CA2434490A1 (en) 2002-07-25
HK1070903A1 (zh) 2005-06-30
CN101555283A (zh) 2009-10-14
JP4384852B2 (ja) 2009-12-16
EP1961767A3 (de) 2008-10-29
US7326415B2 (en) 2008-02-05
DE60230482D1 (de) 2009-02-05

Similar Documents

Publication Publication Date Title
DE60230482D1 (de) Antikörper gegen nichtfunktionelle p 2 x 7 rezeptoren, diagnose und behandlung von krebs und anderen leiden
DE60023148D1 (de) Amine and amide als ligande für den neuropeptid-y y5 rezeptor, und ihre anwendung zur behandlung von fettleibigkeit und anderen erkrankungen
EP1385421A4 (de) Identifizierung, diagnose und behandlung von neuropathologien, neurotoxizität, tumoren und gehirn- und rückenmarksverletzungen durch mikroelektroden mit mikrovoltammetrie
DE60022754D1 (de) Diagnose und behandlung von arrhythmien
TR200401871T4 (tr) Değiştirilen oktanoil amitlerin (octanoyl amides) hazırlanması
ATE556092T1 (de) Mittel zur diagnose und therapie von ctcl
ATE306481T1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
ATE451477T1 (de) Diagnose und überwachung von hepatozellulärem karzinom
ATE446285T1 (de) Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3- thiosubstituierte indol-2-alkinsäuren
PT1360187E (pt) 3,7-diazabiciclo(3.3.0)octanos e a sua utilizacao no tratamento de arritmias cardiacas
TR199903014T2 (xx) 5-HT1F Agonistleri olarak yararl� karboksamitler.
EA199800666A1 (ru) Применение lhrh-аналога или комбинации lhrh-аналогов и антиэстрогена с селективным по отношению к тканям эстрогенным действием для лечения гинекологических нарушений
DE69019553D1 (de) Wärmepumpenkompressor und Betriebsverfahren für den Kompressor.
NO20000731D0 (no) Neisseria-lactodweeinbindingsprotein
DE602004014020D1 (de) Prävention und behandlung von hypertonen herzerkrankungen mit den selektiven östrogenen 8beta-vinyl-estra-1,3,5(10)-trien-3,17beta-diol und 17beta-fluor-9alpha-vinyl-estra-1,3,5(10)-trien-3,16alpha-diol
DE69835519D1 (de) Verfahren und zusammensetzungen für die diagnose und die behandlung von krankheiten, die mit eisenüberschuss oder eisenmangel assoziiert sind.
ITTO20000674A0 (it) Composizioni a base di aminoacidi, atte al trattamento dell'insufficienza cardiaca.
DE69805988D1 (de) Herstellung von 1,3-diaminopentan durch hydrierung von 3-aminopentanitril
EA200000875A1 (ru) Белки, взаимодействующие с каспазой-8
ATE373718T1 (de) 17867, eine menschliche aminopeptidase
DE3767731D1 (de) Prostacyclinanalog, dieses als aktives bestandteil enthaltendes, den blutumlauf verbesserndes mittel und gegen magengeschwuere wirkendes mittel.
EP1435962A4 (de) Behandlung von diabetes vom typ 1
ATE205529T1 (de) Reninaktive substanz enthaltend humanes prorenin und antikörper gegen das prorenin profragment
ATE429489T1 (de) Menschliche carnosinase 2
EP1357834A4 (de) Diagnose von atmungsstörungen im schlaf